abacavir + lamivudine + nevirapine

The combination "abacavir + lamivudine + nevirapine" is an antiretroviral medication used to treat HIV/AIDS. This combination includes two nucleoside reverse transcriptase inhibitors (NRTIs) - abacavir and lamivudine - along with nevirapine, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Abacavir and lamivudine are available together as a fixed-dose combination under brand names like Kivexa and Epzicom[5]. Abacavir is a synthetic carbocyclic nucleoside analogue that is converted to the active metabolite carbovir triphosphate, which competes with endogenous dGTP and blocks its incorporation into HIV viral DNA, resulting in termination of chain elongation and inhibition of viral replication[4][7]. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor that works similarly to prevent HIV replication[4]. While the search results don't specifically mention the triple combination with nevirapine, they do show that abacavir and lamivudine are commonly used in combination with other antiretroviral agents for HIV treatment[1][5][9]. The combination would be used to treat HIV-1 infection by targeting the virus through multiple mechanisms, helping to reduce viral load and slow the progression of the disease. Like other HIV medications, this combination would not cure HIV/AIDS but would help manage the condition by suppressing viral replication[1][9]. Common side effects of abacavir and lamivudine include headache, nausea, fatigue, sleep disturbances, and rash[6][8]. Serious side effects can include hypersensitivity reactions (particularly with abacavir), lactic acidosis, and liver problems[8][10]. It's important to note that abacavir can cause serious, potentially fatal hypersensitivity reactions, especially in patients with the HLA-B*5701 gene variation, which should be tested for before starting treatment[10].

Other names

nevirapine + abacavir + lamivudine